[go: up one dir, main page]

CL2019002769A1 - Procesos para la producción de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia. - Google Patents

Procesos para la producción de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia.

Info

Publication number
CL2019002769A1
CL2019002769A1 CL2019002769A CL2019002769A CL2019002769A1 CL 2019002769 A1 CL2019002769 A1 CL 2019002769A1 CL 2019002769 A CL2019002769 A CL 2019002769A CL 2019002769 A CL2019002769 A CL 2019002769A CL 2019002769 A1 CL2019002769 A1 CL 2019002769A1
Authority
CL
Chile
Prior art keywords
tils
closed
immunotherapy
processes
production
Prior art date
Application number
CL2019002769A
Other languages
English (en)
Inventor
Seth Wardell
Louis Beardell
Michael T Lotze
Original Assignee
Iovance Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61569356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019002769(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Iovance Biotherapeutics Inc filed Critical Iovance Biotherapeutics Inc
Publication of CL2019002769A1 publication Critical patent/CL2019002769A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/04—Immunosuppressors, e.g. cyclosporin, tacrolimus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA MEJORES MÉTODOS Y/O MÉTODOS ACORTADOS PARA EXPANDIR TILS Y PRODUCIR POBLACIONES TERAPÉUTICAS DE TILS, INCLUYENDO NUEVOS MÉTODOS PARA EXPANDIR LAS POBLACIONES DE TILS EN UN SISTEMA CERRADO QUE LLEVAN A UNA MAYOR EFICACIA, MAYOR FENOTIPO Y MAYOR SALUD METABÓLICA DE LOS TILS EN UN PERÍODO DE TIEMPO MÁS CORTO, MIENTRAS PERMITE UNA CONTAMINACIÓN MICROBIANA REDUCIDA ASÍ COMO MENORES COSTOS. ESTOS TILS SE USAN EN REGÍMENES DE TRATAMIENTO TERAPÉUTICOS.
CL2019002769A 2017-03-29 2019-09-27 Procesos para la producción de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia. CL2019002769A1 (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762478506P 2017-03-29 2017-03-29
US201762539410P 2017-07-31 2017-07-31
US201762548306P 2017-08-21 2017-08-21
US201762554538P 2017-09-05 2017-09-05
US201762559374P 2017-09-15 2017-09-15
US201762567121P 2017-10-02 2017-10-02
US201762577655P 2017-10-26 2017-10-26
US201762582874P 2017-11-07 2017-11-07
US201762596374P 2017-12-08 2017-12-08

Publications (1)

Publication Number Publication Date
CL2019002769A1 true CL2019002769A1 (es) 2020-05-08

Family

ID=61569356

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019002769A CL2019002769A1 (es) 2017-03-29 2019-09-27 Procesos para la producción de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia.
CL2020002737A CL2020002737A1 (es) 2017-03-29 2020-10-22 Métodos para expandir linfocitos infiltrantes de tumores (divisional de la solicitud no. 201902769)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2020002737A CL2020002737A1 (es) 2017-03-29 2020-10-22 Métodos para expandir linfocitos infiltrantes de tumores (divisional de la solicitud no. 201902769)

Country Status (35)

Country Link
US (60) US10894063B2 (es)
EP (6) EP3601533B1 (es)
JP (6) JP7169291B2 (es)
KR (2) KR20240114787A (es)
CN (1) CN110785486A (es)
AU (2) AU2018243355B2 (es)
BR (1) BR112019020326A2 (es)
CA (1) CA3057975A1 (es)
CL (2) CL2019002769A1 (es)
CO (1) CO2019011995A2 (es)
CR (1) CR20190487A (es)
CY (1) CY1124136T1 (es)
DK (3) DK3601533T3 (es)
EC (1) ECSP19077884A (es)
ES (3) ES3008832T3 (es)
FI (2) FI3730608T3 (es)
HR (3) HRP20250068T1 (es)
HU (3) HUE070176T2 (es)
IL (2) IL305198A (es)
JO (1) JOP20190224A1 (es)
LT (3) LT3601533T (es)
MA (2) MA68598B1 (es)
MD (3) MD3601533T2 (es)
MX (2) MX2019011768A (es)
PE (1) PE20191841A1 (es)
PH (1) PH12019502247A1 (es)
PL (3) PL3730608T3 (es)
PT (3) PT3601533T (es)
RS (3) RS66452B1 (es)
SG (1) SG11201908994RA (es)
SI (3) SI3730608T1 (es)
SM (3) SMT202100298T1 (es)
TN (1) TN2019000273A1 (es)
TW (1) TWI799402B (es)
WO (1) WO2018182817A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618878B2 (en) 2017-01-13 2023-04-04 Instil Bio (Uk) Limited Aseptic tissue processing method, kit and device
US11767510B2 (en) 2019-12-20 2023-09-26 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111643524B (zh) 2013-03-01 2023-09-05 美国卫生和人力服务部 从外周血中产生肿瘤反应性t细胞富集群的方法
GB201522097D0 (en) 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
SMT202400133T1 (it) 2016-10-26 2024-05-14 Iovance Biotherapeutics Inc Restimolazione di linfociti infiltranti il tumore crioconservati
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
EP3565586B1 (en) 2017-01-06 2025-10-08 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
AU2018234810B2 (en) 2017-03-15 2023-05-11 Pandion Operations, Inc. Targeted immunotolerance
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
JP2020522516A (ja) 2017-06-05 2020-07-30 アイオバンス バイオセラピューティクス，インコーポレイテッド 二重抵抗性黒色腫において腫瘍浸潤リンパ球を使用する方法
AU2018368786B2 (en) 2017-11-17 2025-05-22 Iovance Biotherapeutics, Inc. TIL expansion from fine needle aspirates and small biopsies
MX2020005041A (es) 2017-11-21 2020-10-12 Univ Leland Stanford Junior Agonistas parciales de interleucina-2.
JP2021503885A (ja) 2017-11-22 2021-02-15 アイオバンス バイオセラピューティクス，インコーポレイテッド 末梢血からの末梢血リンパ球（ｐｂｌ）の拡大培養
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
KR20200119242A (ko) 2018-01-08 2020-10-19 이오반스 바이오테라퓨틱스, 인크. 종양 항원-특이적 t-세포에 대해 풍부화된 til 생성물의 생성 방법
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
KR20200133219A (ko) 2018-03-15 2020-11-26 케이에스큐 세러퓨틱스 인코포레이티드 개선된 면역요법을 위한 유전자-조절 조성물 및 방법
BR112020018658A2 (pt) 2018-03-15 2020-12-29 KSQ Therapeutics, Inc. Composições de regulação gênica e métodos para imu-noterapia aprimorada
EA202092319A1 (ru) * 2018-03-29 2021-03-04 Айовэнс Байотерапьютикс, Инк. Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии
TW202446952A (zh) 2018-04-27 2024-12-01 美商艾歐凡斯生物治療公司 腫瘤浸潤性淋巴細胞之基因編輯和彼於免疫治療之用途
US12473532B2 (en) 2018-05-10 2025-11-18 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
AU2019360928B2 (en) 2018-10-15 2023-11-09 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
JP2022506508A (ja) * 2018-11-05 2022-01-17 アイオバンス バイオセラピューティクス，インコーポレイテッド Ａｋｔ経路阻害剤を利用したｔｉｌの拡大培養
ES3021682T3 (en) * 2018-11-05 2025-05-27 Iovance Biotherapeutics Inc Tumour infiltrating lymphocytes for use in treating nsclc patients refractory to anti-pd-1 antibodies
MX2021004953A (es) * 2018-11-05 2021-08-11 Iovance Biotherapeutics Inc Seleccion de celulas t reactivas al tumor mejoradas.
CN113272421B (zh) 2018-11-05 2025-02-18 艾欧凡斯生物治疗公司 用于产生肿瘤浸润性淋巴细胞的方法及其在免疫疗法中的用途
EP3877509A1 (en) * 2018-11-08 2021-09-15 GammaDelta Therapeutics Limited Methods for isolating and expanding cells
US20220193131A1 (en) * 2018-12-19 2022-06-23 Iovance Biotherapeutics, Inc. Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
US20220112557A1 (en) 2019-01-10 2022-04-14 Iovance Biotherapeutics, Inc. System and methods for monitoring adoptive cell therapy clonality and persistence
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
WO2021006316A1 (ja) * 2019-07-10 2021-01-14 国立研究開発法人国立がん研究センター がん細胞を特異的に攻撃しているｔ細胞を同定するための特異的マーカー
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
JP2022544358A (ja) * 2019-08-12 2022-10-18 ベリカム ファーマシューティカルズ， インコーポレイテッド 免疫細胞のための改良された製剤
EP4017964A1 (en) 2019-08-19 2022-06-29 Universität Basel Cell therapy methods
AU2020353015A1 (en) * 2019-09-24 2022-03-31 Nurix Therapeutics, Inc. CBL inhibitors and compositions for use in adoptive cell therapy
CA3155727A1 (en) * 2019-10-25 2021-04-29 Cecile Chartier-Courtaud Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2023504147A (ja) 2019-12-04 2023-02-01 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介したｂｔｋの分解のための二官能性化合物
CA3161104A1 (en) * 2019-12-11 2021-06-17 Cecile Chartier-Courtaud Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine, Inc. Biased il2 muteins methods and compositions
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2021216920A1 (en) * 2020-04-22 2021-10-28 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
BR112022021551A2 (pt) 2020-04-28 2023-01-03 Lyell Immunopharma Inc Métodos para cultivar células
CN115461062A (zh) 2020-04-28 2022-12-09 阿基里斯治疗英国有限公司 T细胞疗法
US20230193203A1 (en) * 2020-04-30 2023-06-22 The Translational Genomics Research Institute Neoantigen-informed tumor-infiltrating lymphocyte cancer immunotherapy
EP4146793A1 (en) * 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
JP7785699B2 (ja) * 2020-05-29 2025-12-15 シャンハイ ジュンセル セラピューティクス カンパニー リミテッド 腫瘍浸潤リンパ球の種細胞培地及びその使用
CN111876381A (zh) * 2020-07-22 2020-11-03 中美冠科生物技术（太仓）有限公司 一种t细胞模型及其在体外人源pd-1抗体药效评价中的应用
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022109501A2 (en) 2020-11-23 2022-05-27 Lyell Immunopharma, Inc. Methods for culturing immune cells
US20240238271A1 (en) 2020-11-25 2024-07-18 Shanghai Juncell Therapeutics Co., Ltd. Pharmaceutical composition for enhancing cell killing, and use thereof
WO2022111571A1 (zh) 2020-11-25 2022-06-02 上海君赛生物科技有限公司 肿瘤浸润淋巴细胞培养基及其应用
JP2024501452A (ja) * 2020-12-11 2024-01-12 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｂｒａｆ阻害剤及び／またはｍｅｋ阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
CA3202483A1 (en) * 2020-12-17 2022-06-23 Maria Fardis Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
EP4263808A2 (en) * 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
AU2021400069A1 (en) * 2020-12-18 2023-07-06 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
CN114686430A (zh) * 2020-12-31 2022-07-01 上海赛比曼生物科技有限公司 一种制备til的方法
US20240110152A1 (en) 2020-12-31 2024-04-04 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
EP4273234A4 (en) * 2021-01-04 2025-04-23 Thyas Co. Ltd. Method for producing a regenerated T cell via an IPS cell
CA3206549A1 (en) * 2021-01-29 2022-08-04 Frederick G. Vogt Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
EP4298208A1 (en) 2021-02-25 2024-01-03 Lyell Immunopharma, Inc. Methods for culturing cells
AR126323A1 (es) 2021-03-05 2023-10-04 Iovance Biotherapeutics Inc Composiciones para el almacenamiento de tumores y cultivos celulares
TW202304480A (zh) * 2021-03-19 2023-02-01 美商艾歐凡斯生物治療公司 腫瘤浸潤淋巴球（ｔｉｌ）中之與ｃｄ３９／ｃｄ６９選擇及基因剔除相關之ｔｉｌ擴增之方法
EP4314253A2 (en) * 2021-03-25 2024-02-07 Iovance Biotherapeutics, Inc. Methods and compositions for t-cell coculture potency assays and use with cell therapy products
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
IL307800A (en) 2021-04-19 2023-12-01 Iovance Biotherapeutics Inc Chimeric costimulatory receptors, chemokine receptors and their use in cellular immunotherapy
WO2022229884A2 (en) 2021-04-27 2022-11-03 Takeda Pharmaceutical Company Limited Recombinant antigen presenting cells
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
DE102021002748A1 (de) 2021-05-27 2022-12-01 Zellwerk Gmbh Verfahren zur Herstellung von Tumor-infiltrierten T-Lymphozyten (TIL) und deren Verwendung als Zell-Therapeutika für die Behandlung humaner Tumoren
CA3223030A1 (en) * 2021-06-17 2022-12-22 CBio A/S Multistep process for culturing tumor-infiltrating lymphocytes for therapeutic use
US20240287456A1 (en) 2021-06-22 2024-08-29 Achilles Therapeutics Uk Limited A method for producing antigen-specific t cells
CA3226111A1 (en) 2021-07-22 2023-01-26 Iovance Biotherapeutics, Inc. Method for cryopreservation of solid tumor fragments
TW202327631A (zh) 2021-07-28 2023-07-16 美商艾歐凡斯生物治療公司 利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者
US20240424097A1 (en) 2021-09-09 2024-12-26 Iovance Biotherapeutics, Inc. Processes for generating til products using pd-1 talen knockdown
JP2024534581A (ja) 2021-09-24 2024-09-20 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球のための拡張プロセス及び薬剤
JP2024542984A (ja) 2021-10-26 2024-11-19 ニューリックス セラピューティクス，インコーポレイテッド がんを治療および予防するためのピペリジニルピラジン－カルボキサミド化合物、およびｂｔｋを分解するためのピペリジニルピラジン－カルボキサミド化合物
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
IL312027A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing immune cells
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023137471A1 (en) 2022-01-14 2023-07-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
EP4463549A2 (en) 2022-01-14 2024-11-20 Tune Therapeutics, Inc. Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
US20250099588A1 (en) 2022-01-28 2025-03-27 Iovance Biotherapeutics, Inc. Cytokine associated tumor infiltrating lymphocytes compositions and methods
EP4469066A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023196877A1 (en) 2022-04-06 2023-10-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2023201369A1 (en) * 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
CA3251533A1 (en) 2022-05-10 2023-11-16 Iovance Biotherapeutics, Inc. TREATMENT OF CANCER PATIENTS WITH TUMOR-INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH AN IL-15R AGONIST
EP4551681A1 (en) 2022-07-06 2025-05-14 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
GB202210006D0 (en) 2022-07-07 2022-08-24 Achilles Therapeutics Uk Ltd Analysis of T cell samples
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
TW202426634A (zh) 2022-09-09 2024-07-01 美商艾歐凡斯生物治療公司 使用ｐｄ─１／ｔｉｇｉｔ ｔａｌｅｎ雙重基因減弱生成ｔｉｌ產物之方法
CA3267183A1 (en) 2022-09-09 2024-03-14 Brittany BUNCH PROCESSES FOR GENERING TIL PRODUCTS USING DOUBLE TALEN INACTIVATION OF PD-1/TIGIT
US12181192B2 (en) * 2022-09-16 2024-12-31 Black & Decker, Inc. Methods and devices for controlling the temperature of a surface
EP4590821A2 (en) 2022-09-19 2025-07-30 Tune Therapeutics, Inc. Compositions, systems, and methods for modulating t cell function
JP2025537155A (ja) 2022-11-04 2025-11-14 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｃｄ３９／ｃｄ１０３選択に関連した腫瘍浸潤リンパ球（ｔｉｌ）拡張のための方法
EP4623072A2 (en) 2022-11-21 2025-10-01 Iovance Biotherapeutics, Inc. Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
CN120225666A (zh) 2022-11-21 2025-06-27 艾欧凡斯生物治疗公司 用于评估基因编辑的t细胞的增殖效力的方法
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
DE102023002417B3 (de) 2023-06-15 2024-12-05 Zellwerk Gmbh Verfahren zur Expansion von Zellen
WO2025006811A1 (en) 2023-06-27 2025-01-02 Lyell Immunopharma, Inc. Methods for culturing immune cells
WO2025015318A2 (en) 2023-07-13 2025-01-16 Iovance Biotherapeutics, Inc. Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
WO2025029835A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for modulating il-2 gene expression
WO2025029840A1 (en) 2023-07-31 2025-02-06 Tune Therapeutics, Inc. Compositions and methods for multiplexed activation and repression of t cell gene expression
WO2025038289A1 (en) * 2023-08-17 2025-02-20 H. Lee Moffitt Cancer Center And Research Institute Inc. Using 12 chemokine signature to select sting agonist and til treatments for solid tumors
WO2025047660A1 (ja) * 2023-08-31 2025-03-06 国立大学法人筑波大学 腫瘍性濾胞制御性ｔ細胞及び腫瘍性濾胞殺細胞性ｔ細胞を定量する方法、腫瘍性濾胞制御性ｔ細胞及び腫瘍性濾胞殺細胞性ｔ細胞をスクリーニングする方法、治療用組成物、及びキット
WO2025054540A1 (en) 2023-09-08 2025-03-13 Iovance Biotherapeutics, Inc. Methods of gene-editing using programmable nucleases
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
CN118710478B (zh) * 2024-08-27 2025-01-03 福州大学 基于改进麻雀搜索算法的地铁突发运营中断客流疏运方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
CN1507357A (zh) 2000-10-31 2004-06-23 PRҩƷ���޹�˾ 提高生物活性分子传递的方法和组合物
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004003142A2 (en) 2002-06-28 2004-01-08 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
ES2602145T3 (es) 2002-09-06 2017-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inmunoterapia con linfocitos específicos de antígeno seleccionados in vitro después de quimioterapia supresora de linfocitos no mieloablativa
ITMI20022118A1 (it) 2002-10-04 2004-04-05 Abiogen Pharma Spa Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo.
CN103173354B (zh) 2003-10-08 2017-07-14 威尔森沃尔夫制造公司 利用透气性材料进行细胞培养的方法及装置
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
WO2007071390A1 (en) 2005-12-21 2007-06-28 Sentoclone Ab Method for treating malignant melanoma
RU2399382C2 (ru) 2005-12-21 2010-09-20 Сентоклон Аб Улучшенный способ увеличения числа опухоле-реактивных т-лимфоцитов в иммунотерапии онкологических больных
US8007785B2 (en) 2005-12-21 2011-08-30 Sentoclone International Ab Method for treating colon cancer with tumour-reactive T-lymphocytes
US8211425B2 (en) 2005-12-21 2012-07-03 Sentoclone International Ab Method for treating disseminated cancer
FR2911346B1 (fr) * 2007-01-12 2012-12-07 Ct Hospitalier Universitaire De Nantes Procede de culture in vitro de lymphocytes t,en particulier de lymphocytes t infiltrant les tumeurs dits til
US7951365B2 (en) 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
EP2203746B1 (en) * 2007-09-24 2013-03-06 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
US20150320798A1 (en) 2012-11-27 2015-11-12 The Johns Hopkins University Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
EP2698430A3 (en) 2009-12-08 2014-03-05 Wilson Wolf Manufacturing Corporation Methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
KR20200070407A (ko) 2010-11-12 2020-06-17 넥타르 테라퓨틱스 Ｉｌ-2 부분 및 중합체의 접합체
US20120244133A1 (en) * 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US9476028B2 (en) 2011-04-13 2016-10-25 Immunicum Ab Method for proliferation of antigen-specific T cells
AU2012324644B2 (en) * 2011-10-21 2014-08-28 Cell Medica Limited Device for the aseptic expansion of cells
GB201121308D0 (en) * 2011-12-12 2012-01-25 Cell Medica Ltd Process
CN102816734A (zh) 2012-05-09 2012-12-12 阮润生 一种肿瘤抗原特异性t细胞的获取方法
SG10202111564SA (en) 2012-05-18 2021-12-30 Wilson Wolf Mfg Corporation Improved methods of cell culture for adoptive cell therapy
EP2859093A4 (en) 2012-06-11 2016-08-17 Wolf Wilson Mfg Corp IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES
EP2925329B1 (en) 2012-11-27 2021-01-06 Borrello, Ivan Marques Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
CA2902423C (en) 2013-03-01 2021-06-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
CN111643524B (zh) 2013-03-01 2023-09-05 美国卫生和人力服务部 从外周血中产生肿瘤反应性t细胞富集群的方法
CN118562610A (zh) 2013-06-24 2024-08-30 威尔逊沃夫制造公司 用于透气性细胞培养过程的封闭系统装置和方法
ES3034357T3 (en) * 2013-07-15 2025-08-18 Us Health Methods of preparing anti-human papillomavirus antigen t cells
US10233425B2 (en) 2013-09-16 2019-03-19 The Trustees Of The University Of Pennsylvania CD137 enrichment for efficient tumor infiltrating lymphocyte selection
CA2943389C (en) 2014-03-20 2023-10-31 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tumor-infiltrating lymphocytes for adoptive cell therapy
EP3154350B1 (en) 2014-04-10 2024-03-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
CN106459917B (zh) 2014-04-23 2021-03-09 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
MX389827B (es) 2014-06-11 2025-03-20 Polybiocept Gmbh Composición para expandir in vitro linfocitos que tiene interleucina 2 (il-2), interleucina 15 (il-15) e interleucina 21 (il-21).
EP3155426B1 (en) 2014-06-13 2023-07-19 Immudex ApS General detection and isolation of specific cells by binding of labeled molecules
WO2016037054A1 (en) 2014-09-04 2016-03-10 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
US20170218042A1 (en) 2014-10-02 2017-08-03 The United State of America, as represented by the Secretary, Department of Health and Human Service Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
AU2016258845B2 (en) 2015-05-01 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
FR3040396A1 (fr) 2015-06-30 2017-03-03 Chu Nantes Procede de cryoconservation de lymphocytes infiltrant la tumeur
FR3038324B1 (fr) 2015-06-30 2020-10-30 Lab Francais Du Fractionnement Procede de cryoconservation de cellules a visee therapeutique
WO2017048614A1 (en) 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating tumor-reactive t cell receptors from tumor or peripheral blood
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
HK1256737A1 (zh) 2015-10-28 2019-10-04 Life Technologies As 通过改变细胞表面信号和信号比选择性扩增不同的t细胞亚群
US20200237819A1 (en) 2016-06-28 2020-07-30 Geneius Biotechnology, Inc. T cell compositions for immunotherapy
CN106244538A (zh) 2016-08-04 2016-12-21 英普乐孚生物技术(上海)有限公司 一种恶性腹水来源的til细胞的分离培养方法
KR20230114331A (ko) 2016-09-14 2023-08-01 애브비 바이오테라퓨틱스 인크. 항-pd-1 항체 및 이의 용도
SMT202400133T1 (it) 2016-10-26 2024-05-14 Iovance Biotherapeutics Inc Restimolazione di linfociti infiltranti il tumore crioconservati
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
KR102618948B1 (ko) 2016-11-17 2023-12-27 이오반스 바이오테라퓨틱스, 인크. 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법
US20200095547A1 (en) 2016-12-02 2020-03-26 Darya ALIZADEH Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
CN106591232A (zh) 2017-01-04 2017-04-26 安徽安龙基因医学检验所有限公司 一种高效的pd‑1‑cd8+t细胞的培养方法
EP3565888A1 (en) 2017-01-06 2019-11-13 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
EP3565586B1 (en) 2017-01-06 2025-10-08 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
KR102771581B1 (ko) 2017-03-14 2025-02-25 주노 쎄러퓨티크스 인코퍼레이티드 극저온 보관 방법
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
MA50871A (fr) 2017-05-10 2020-03-18 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant des tumeurs à partir de tumeurs liquides et leurs utilisations thérapeutiques
JP2020522516A (ja) 2017-06-05 2020-07-30 アイオバンス バイオセラピューティクス，インコーポレイテッド 二重抵抗性黒色腫において腫瘍浸潤リンパ球を使用する方法
CN107384867B (zh) 2017-08-04 2020-09-11 北京世纪劲得生物技术有限公司 一种肿瘤组织til细胞制备方法及专用培养基
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
WO2021216920A1 (en) 2020-04-22 2021-10-28 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618878B2 (en) 2017-01-13 2023-04-04 Instil Bio (Uk) Limited Aseptic tissue processing method, kit and device
US11618877B2 (en) 2017-01-13 2023-04-04 Instil Bio (Uk) Limited Aseptic tissue processing method, kit and device
US11767510B2 (en) 2019-12-20 2023-09-26 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof

Also Published As

Publication number Publication date
US20220008469A1 (en) 2022-01-13
US20220387499A1 (en) 2022-12-08
US20250121009A1 (en) 2025-04-17
US11052115B2 (en) 2021-07-06
US20220378838A1 (en) 2022-12-01
NZ758201A (en) 2024-01-26
US20230045899A1 (en) 2023-02-16
WO2018182817A1 (en) 2018-10-04
PE20191841A1 (es) 2019-12-31
US10894063B2 (en) 2021-01-19
US11291687B2 (en) 2022-04-05
US11040070B2 (en) 2021-06-22
US12485145B2 (en) 2025-12-02
SI3722415T1 (sl) 2025-03-31
US10918666B2 (en) 2021-02-16
US20220000924A1 (en) 2022-01-06
US11202804B2 (en) 2021-12-21
US12194061B2 (en) 2025-01-14
SMT202500040T1 (it) 2025-03-12
JP7522037B2 (ja) 2024-07-24
MX2019011768A (es) 2019-12-09
US11083752B2 (en) 2021-08-10
US20210128625A1 (en) 2021-05-06
JP7169291B2 (ja) 2022-11-10
ES3009885T3 (en) 2025-03-31
LT3722415T (lt) 2025-01-10
US10925900B2 (en) 2021-02-23
US10639330B2 (en) 2020-05-05
US20210207092A1 (en) 2021-07-08
AU2018243355B2 (en) 2024-10-24
LT3601533T (lt) 2021-06-10
SMT202100298T1 (it) 2021-07-12
US20220387495A1 (en) 2022-12-08
EP3730608B1 (en) 2024-10-23
US11202803B1 (en) 2021-12-21
JP2020515257A (ja) 2020-05-28
US20190358259A1 (en) 2019-11-28
US20210361712A1 (en) 2021-11-25
US20190358260A1 (en) 2019-11-28
HUE070256T2 (hu) 2025-05-28
US11541077B2 (en) 2023-01-03
US20180280436A1 (en) 2018-10-04
US20190000883A1 (en) 2019-01-03
US12121541B2 (en) 2024-10-22
KR20190142342A (ko) 2019-12-26
DK3730608T3 (da) 2024-12-16
EP3601533B1 (en) 2021-02-24
US11337998B2 (en) 2022-05-24
US20180282694A1 (en) 2018-10-04
TN2019000273A1 (en) 2021-01-07
CN110785486A (zh) 2020-02-11
US20220387498A1 (en) 2022-12-08
ES3008832T3 (en) 2025-03-25
JP2023012511A (ja) 2023-01-25
US20200306306A1 (en) 2020-10-01
AU2018243355A1 (en) 2019-10-31
US10946044B2 (en) 2021-03-16
US20190083539A1 (en) 2019-03-21
US12226434B2 (en) 2025-02-18
US20210100843A1 (en) 2021-04-08
RS66452B1 (sr) 2025-02-28
US20230012086A1 (en) 2023-01-12
RS61863B1 (sr) 2021-06-30
US20210128622A1 (en) 2021-05-06
US20210079348A1 (en) 2021-03-18
BR112019020326A2 (pt) 2020-04-28
US20210353677A1 (en) 2021-11-18
JP2025023951A (ja) 2025-02-19
US20220387497A1 (en) 2022-12-08
US20250121008A1 (en) 2025-04-17
US20210106625A1 (en) 2021-04-15
CR20190487A (es) 2020-03-17
US20190083538A1 (en) 2019-03-21
EP4279574A2 (en) 2023-11-22
AU2025200434A1 (en) 2025-02-20
US20220395533A1 (en) 2022-12-15
US20220387496A1 (en) 2022-12-08
MA68856B1 (fr) 2025-01-31
EP4279574A3 (en) 2024-04-10
EP3722415A1 (en) 2020-10-14
US20220000923A1 (en) 2022-01-06
EP3730608A1 (en) 2020-10-28
EP3722415B1 (en) 2024-11-06
US10166257B2 (en) 2019-01-01
CO2019011995A2 (es) 2020-02-18
US11304979B2 (en) 2022-04-19
US10653723B1 (en) 2020-05-19
KR20240114787A (ko) 2024-07-24
US11168304B2 (en) 2021-11-09
PT3730608T (pt) 2025-01-07
DK3722415T3 (da) 2025-01-13
US10272113B2 (en) 2019-04-30
SI3601533T1 (sl) 2021-09-30
US11013770B1 (en) 2021-05-25
US20200155601A1 (en) 2020-05-21
PT3601533T (pt) 2021-05-24
US10953046B2 (en) 2021-03-23
US11529372B1 (en) 2022-12-20
HUE054829T2 (hu) 2021-10-28
US20210128623A1 (en) 2021-05-06
US20220000925A1 (en) 2022-01-06
JOP20190224A1 (ar) 2019-09-26
ES2874335T3 (es) 2021-11-04
US20200289569A1 (en) 2020-09-17
JP7772680B2 (ja) 2025-11-18
US20210128624A1 (en) 2021-05-06
CA3057975A1 (en) 2018-10-04
US20190070222A1 (en) 2019-03-07
US20190358261A1 (en) 2019-11-28
SI3730608T1 (sl) 2025-03-31
US11007226B2 (en) 2021-05-18
US11344579B2 (en) 2022-05-31
US11273180B2 (en) 2022-03-15
KR102686794B1 (ko) 2024-07-24
US10537595B2 (en) 2020-01-21
TWI799402B (zh) 2023-04-21
US20210128621A1 (en) 2021-05-06
US10463697B2 (en) 2019-11-05
PT3722415T (pt) 2025-01-08
SG11201908994RA (en) 2019-10-30
HRP20241688T1 (hr) 2025-02-14
US11007225B1 (en) 2021-05-18
US10398734B2 (en) 2019-09-03
MD3722415T2 (ro) 2025-05-31
MD3730608T2 (ro) 2025-03-31
US11168303B2 (en) 2021-11-09
US10946045B2 (en) 2021-03-16
CY1124136T1 (el) 2022-05-27
US11517592B1 (en) 2022-12-06
US11273181B2 (en) 2022-03-15
US20190083536A1 (en) 2019-03-21
US20200276241A1 (en) 2020-09-03
US20210137984A1 (en) 2021-05-13
PL3730608T3 (pl) 2025-03-31
US20210379111A1 (en) 2021-12-09
TW201839129A (zh) 2018-11-01
US10905718B2 (en) 2021-02-02
US20230133298A1 (en) 2023-05-04
JP2021519582A (ja) 2021-08-12
US20190000882A1 (en) 2019-01-03
DK3601533T3 (da) 2021-05-03
IL305198A (en) 2023-10-01
US20180207201A1 (en) 2018-07-26
SMT202500027T1 (it) 2025-03-12
US20220362301A1 (en) 2022-11-17
HRP20250068T1 (hr) 2025-03-14
JP2023012510A (ja) 2023-01-25
ECSP19077884A (es) 2020-01-31
US20250082683A1 (en) 2025-03-13
US20210128620A1 (en) 2021-05-06
MA68598B1 (fr) 2025-01-31
IL269543A (en) 2019-11-28
FI3730608T3 (fi) 2024-12-30
CL2020002737A1 (es) 2021-03-05
US11998568B2 (en) 2024-06-04
US20200281978A1 (en) 2020-09-10
US10646517B2 (en) 2020-05-12
US20210361713A1 (en) 2021-11-25
US20210100842A1 (en) 2021-04-08
PL3722415T3 (pl) 2025-03-31
US10695372B2 (en) 2020-06-30
MD3601533T2 (ro) 2021-07-31
US10363273B2 (en) 2019-07-30
EP3601533A1 (en) 2020-02-05
RS66400B1 (sr) 2025-02-28
US10953047B2 (en) 2021-03-23
US20200246384A1 (en) 2020-08-06
US20200276242A1 (en) 2020-09-03
FI3722415T3 (fi) 2025-01-10
US20230015649A1 (en) 2023-01-19
US20210214685A1 (en) 2021-07-15
US11052116B2 (en) 2021-07-06
US20210207091A1 (en) 2021-07-08
PH12019502247A1 (en) 2020-06-29
US11241456B2 (en) 2022-02-08
US10933094B2 (en) 2021-03-02
US10130659B2 (en) 2018-11-20
US20220387494A1 (en) 2022-12-08
US10420799B2 (en) 2019-09-24
US20180325954A1 (en) 2018-11-15
PL3601533T3 (pl) 2021-08-16
JP2023011778A (ja) 2023-01-24
MX2024002827A (es) 2024-03-19
HRP20210677T1 (hr) 2021-06-25
EP3766964A1 (en) 2021-01-20
US20200306307A1 (en) 2020-10-01
EP3910055A1 (en) 2021-11-17
LT3730608T (lt) 2024-12-27
HUE070176T2 (hu) 2025-05-28

Similar Documents

Publication Publication Date Title
CL2019002769A1 (es) Procesos para la producción de linfocitos infiltrantes de tumores y usos de ellos en inmunoterapia.
CO2021007362A2 (es) Procesos para la producción de linfocitos infiltrantes de tumor y usos de estos en inmunoterapia
MX2020011134A (es) Proceso cerrado para expansion y edicion de genes de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia.
MX2020010264A (es) Procesos para la produccion de linfocitos infiltrantes en tumor y usos de los mismos en inmunoterapia.
IL283325A (en) Methods for treatment using adoptive cell therapy
BR112017014269A2 (pt) células exterminadoras naturais e usos das mesmas
MX2017017079A (es) Sistema de administracion dirigida de principio activo celular.
CL2018001108A1 (es) Composiciones y métodos para transducción de tumores
NZ731789A (en) Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
MX384175B (es) Métodos para seleccionar una línea de células t y el donador de la misma para terapia celular adoptiva.
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
ZA201903605B (en) Modified oligonucleotides for treatment of polycystic kidney disease
MX2018012230A (es) Métodos para tratar enfermedades oculares.
CY1124492T1 (el) 7-υποκατεστημενα 1-αρυλο-ναφθυριδιν-3-καρβοξαμιδια και η χρηση αυτων
MY202466A (en) Methods for treatment of polycystic kidney disease
AR126650A2 (es) Procesos para producir linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia
AR110733A1 (es) Procesos para producir linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia
AR122009A1 (es) Procesos para producción de linfocitos infiltrantes del tumor y usos de los mismos en inmunoterapia
UA112357C2 (uk) Спосіб індивідуальної цільової терапії дефіциту вітаміну d у пацієнтів із захворюваннями кістково-м'язової системи
AR119647A1 (es) Edición de genes de linfocitos infiltrantes de tumor y usos de los mismos en inmunoterapia
UA130638U (uk) Спосіб природного омолодження організму людини
UA97357U (en) Method for laser therapy in the treatment of patients with exogenous depressive disorder with suicidal behavior
MA50030A (fr) Traitement du cancer par stimulation de la production d'il-12
UA108546U (uk) Спосіб лікування хворих на лімфому ходжкіна іів стадії